Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Politics

VP Harris credits nonexistent federal agency with approving mifepristone: watch

by April 24, 2023
April 24, 2023
VP Harris credits nonexistent federal agency with approving mifepristone: watch

Vice President Kamala Harris mistakenly said last week that a government agency called the ‘Federal Drug Administration’ approved the abortion pill mifepristone 20 years ago.

While the Federal Drug Administration may seem to be the likely breakdown of the acronym for FDA, the correct agency is the Food and Drug Administration (FDA).

Harris sat down for an interview with Noticias Telemundo’s Vanessa Hauc, which aired Friday evening, where the vice president spoke about abortion and the changes taking place in the U.S.

‘Let’s set the scene. Many months ago, the highest court in our land, the United States Supreme Court, took a constitutional right that had been recognized from the people of America – from the women of America – which is the right to make [a] decision about your own body and your own reproductive health,’ Harris said. ‘The government should not be telling that woman what to do with her body. This evokes, in my mind, very fundamental rights, including the right to freedom for each individual about what is in their best interest.’

The vice president then turned her attention to mifepristone, an abortion pill approved by the Food and Drug Administration in 2000.

A case challenging the FDA’s approval of the drug, which was brought on by pro-life doctors and medical groups, challenges not the pill directly but whether the FDA acted appropriately when it approved the drug more than 20 years ago.

‘On the mifepristone issue, it’s politicians finding a court, targeting a specific court that they thought would be helpful to them, to take a medication off the market, which was approved 20 years ago by the Federal Drug Administration,’ Harris said.

She then asked anyone to look into their medical cabinet and look at any drug in there that was prescribed by a doctor.

Harris said any of the drugs prescribed, whether to help with pain or extend a person’s quality of life, was FDA approved.

‘Arguably, what they’re doing with mifepristone could happen to any one of those drugs in your medicine cabinet,’ she said.

On Friday, the same day the interview with Harris aired, the Supreme Court ruled that full access to the abortion pill could continue as the lawsuit works its way through the lower federal courts.

The case reached the Supreme Court after Trump-appointed U.S. District Judge Matthew J. Kacsmaryk issued a ruling that sided with pro-life groups by halting the FDA approval of mifepristone.

Kacsmaryk’s order was partially overturned by the 5th U.S. Circuit of Appears, but the appeals court preserved restrictions that made the drug available only to be dispensed up to seven weeks, not 10, and not by mail.

The Justice Department argued that allowing restrictions on the drug to remain in place would create chaos.

Complicating things, a federal judge in Washington ordered the FDA to preserve access to mifepristone under the current rules in response to a separate lawsuit brought by 17 Democrat-led states and the District of Columbia.

Mifepristone is taken with misoprostol in a two-drug regimen that first blocks hormones needed to keep an unborn baby alive and then causes cramps and contractions to expel the dead fetus from the mother’s womb.

The drug is 97% effective in terminating early pregnancy, though approximately 3% of women who take it will ‘require surgical intervention for ongoing pregnancy, heavy bleeding, incomplete expulsion or other reasons such as patient request,’ according to the manufacturer.

Christ Pandolfo, Adam Sabes, Shannon Bream and Bill Mears of Fox News contributed to this report.

Greg Wehner is a breaking news reporter for Fox News Digital.

This post appeared first on FOX NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
Psaki has dessert in ‘hard-hitting interview’ with former boss: ‘Doesn’t ask tough questions either’
next post
Late payments ‘soar’ as pressure grows on suppliers

You may also like

Washington Post Retracts Op-Ed Lamenting the Lack of...

December 13, 2022

Trump slams Iowa’s Republican governor for staying neutral...

July 11, 2023

DAVID MARCUS: As Trump takes office, the forgotten...

January 20, 2025

Meet Edan Alexander, the last living American hostage...

February 22, 2025

Did General David Petraeus Let The Ukrainian Cat...

October 29, 2022

Trump nominates Rep. Lori Chavez-DeRemer as secretary of...

November 23, 2024

Legal experts say RFK Jr.’s move to give...

February 3, 2025

Trump says Biden ‘is not fit to serve’:...

July 21, 2024

The Joke Is On Colbert: After Accusing Tudor...

November 5, 2022

Trump fires back at Jan. 6 criticism, says...

January 6, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Universities in Libertarian Land

      June 6, 2025
    • Elon Musk may speak to Trump aides in push to calm feud

      June 6, 2025
    • Everyone Talks About Leaving a Better Planet for Our Children: Why Don’t We Leave Better Children for Our Planet?

      June 6, 2025
    • MARK HALPERIN: Democrats try to construct a Frankenstein candidate while JD Vance gains momentum for 2028

      June 6, 2025
    • ‘Gone too far’: GOP lawmakers rally around Trump after Musk raises Epstein allegations

      June 6, 2025
    • Democrats begin to embrace Musk amid Trump spat after party railed against him as a ‘dictator’

      June 6, 2025

    Categories

    • Business (8,149)
    • Investing (2,012)
    • Politics (15,544)
    • Stocks (3,130)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved